Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
45.48
-1.66 (-3.53%)
Apr 29, 2026, 10:21 AM EDT - Market open

Company Description

Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally.

The company’s respiratory vaccines include spikevax, mNEXSPIKE, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, such as lyme vaccines.

It also provides oncology therapeutics, such as intismeran autogene, cancer antigen therapy, t-cell engager, and cell therapy enhancer; and rare disease products, including propionic and methylmalonic acidemia, and cystic fibrosis.

It has strategic alliances and collaborations with Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; immatics N.V.; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI.

The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018.

Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.
Moderna logo
Country United States
Founded 2010
IPO Date Dec 7, 2018
Industry Biotechnology
Sector Healthcare
Employees 4,700
CEO Stéphane Bancel

Contact Details

Address:
325 Binney Street
Cambridge, Massachusetts 02142
United States
Phone 617 714 6500
Website modernatx.com

Stock Details

Ticker Symbol MRNA
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001682852
CUSIP Number 60770K107
ISIN Number US60770K1079
Employer ID 81-3467528
SIC Code 2836

Key Executives

Name Position
Stéphane Bancel M.B.A. Chief Executive Officer and Director
Dr. Stephen Hoge M.D. President
James M. Mock Chief Financial Officer
Shannon Thyme Klinger J.D. Chief Legal Officer and Corporate Secretary
Dr. Jerh Collins Ph.D. Chief Technical Operations and Quality Officer
Lavina Talukdar CFA Senior Vice President and Head of Investor Relations
Tracey Franklin Chief People and Digital Technology Officer
Dr. Charbel Haber M.P.H., Ph.D. Senior Vice President and Head of Global Regulatory Science
Patrick Norman Bergstedt Senior Vice President of Commercial Vaccines
Dr. John Lepore J.D., M.D. Senior Vice President of Government Engagement

Latest SEC Filings

Date Type Title
Mar 27, 2026 SCHEDULE 13G/A Filing
Mar 16, 2026 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Mar 16, 2026 DEF 14A Other definitive proxy statements
Mar 16, 2026 ARS Filing
Mar 5, 2026 8-K Current Report
Mar 2, 2026 144 Filing
Feb 23, 2026 144 Filing
Feb 20, 2026 S-8 Securities to be offered to employees in employee benefit plans
Feb 20, 2026 10-K Annual Report
Feb 13, 2026 8-K Current Report